No Data
No Data
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $4
Express News | Clearside Biomedical Shares Are Trading Higher. Needham Reiterated a Buy Rating on the Stock
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD), Biogen (BIIB) and DENTSPLY SIRONA (XRAY)
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
A Quick Look at Today's Ratings for Clearside Biomedical(CLSD.US), With a Forecast Between $4 to $8
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations